ArticleACS omega2025
Cardioprotective and Antihyperlipidemic Effects of
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodsPrediabetic Wistar rats were administered with ExPhy (6.75 mg/kg, 12.50 mg/kg, 75 mg/kg) and Am (500 mg/kg) for 21 days, then the ischemia/reperfusion model was performed (1/4) measuring infarct area vs healthy area, in addition to biochemical lipid tests.
resultsA reduction in cardiac necrotic damage produced by ischemia was found, as well as a reduction in total cholesterol and LDL cholesterol without significant differences in triglycerides and HDL; however, a reduction in the atherogenic index was observed in the doses of ExPhy 12.50 mg/kg and Am 500 mg/kg administered subchronically.
conclusionAm and ExPhy showed cardioprotective and antihyperlipidemic action in the prediabetic rat model, because of its ability to modulate key signaling pathways involved in cell survival, inflammation, and lipid metabolism, hence acting as potential adjuvants against damage caused by cardiac ischemia and reperfusion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.